Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,039 shares of the medical research company's stock after selling 1,715 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in Thermo Fisher Scientific were worth $6,989,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Cypress Advisory Group LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at $253,000. GAMMA Investing LLC boosted its holdings in shares of Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares during the period. Deutsche Bank AG grew its position in Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after purchasing an additional 114,277 shares in the last quarter. Hancock Whitney Corp lifted its position in Thermo Fisher Scientific by 0.6% in the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock worth $2,802,000 after buying an additional 30 shares in the last quarter. Finally, Cetera Trust Company N.A boosted its stake in shares of Thermo Fisher Scientific by 3.3% during the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock valued at $2,312,000 after buying an additional 150 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $449.68 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm's 50-day moving average is $424.58 and its 200-day moving average is $465.66. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a market cap of $169.80 billion, a price-to-earnings ratio of 26.01, a PEG ratio of 2.49 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the company earned $5.37 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TMO. Royal Bank Of Canada reduced their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Argus lowered their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. HSBC restated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Six analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.